Clinical trial
A Phase 1b, Open-label, Single-arm, Dose-escalation Study of PN20 in Patients With Primary Immune Thrombocytopenia (ITP)
NCT06880081 is registered in ClinicalTrials.gov with Chongqing Peg-Bio Biopharm Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b, Open-label, Single-arm, Dose-escalation Study of PN20 in Patients With Primary Immune Thrombocytopenia (ITP)
- Lead sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- March 7, 2025
- Completion date
- April 28, 2026
- Enrollment
- 12 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
primary immune thrombocytopenia (itp)